Dynavax (NASDAQ: DVAX) reported Q4 EPS of $0.00, $0.03 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $55.59 million versus the consensus estimate of $52.4 million.

GUIDANCE:

Dynavax sees FY2024 revenue of $265-280 million, versus the consensus of $290.6 million.

For earnings history and earnings-related data on Dynavax (DVAX) click here.